Clinical Trial Detail

NCT ID NCT02824029
Title Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Barbara Ann Karmanos Cancer Institute
Indications

Hodgkin's lymphoma

Therapies

Ibrutinib

Age Groups: senior adult

No variant requirements are available.